Cadrenal Therapeutics, Inc. Common Stock
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Cadrenal Therapeutics, Inc. Common Stock generated cash of -$3,530,323, which is less than the previous year. Cash used in financing activities reached the amount of $11,903,491 last year. Net change in cash is therefore $8,369,914.
Cash Flow
| 2022 | -1.20M | -2.27K | 1.23M |
|---|---|---|---|
| 2023 | -3.53M | -3.25K | 11.90M |
CVKD Cash Flow Statement (2022 – 2023)
| 2023 | 2022 | |
|---|---|---|
Cash at beginning of period | 32.58K | -1 |
Operating activities | ||
Net income | -8.35M | -6.71M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||
Depreciation and amortization | 1.98K | 1.26K |
Stock-based compensation expense | 710.38K | 0 |
| Deferred income tax benefit | 710.38K | 0 |
| Changes in operating assets and liabilities: | ||
Accounts receivable, net | 0 | 0 |
Inventories | 0 | 0 |
Accounts payable | -237.57K | 404.89K |
Cash generated by operating activities | -3.53M | -1.20M |
Investing activities | ||
Purchases Of Investments | 0 | -2.27K |
Investments In Property Plant And Equipment | -3.25K | 0 |
Acquisitions Net | 0 | 0 |
Cash generated by investing activities | -3.25K | -2.27K |
Financing activities | ||
Common Stock Issued | 11.90M | 1.23M |
Payments for dividends | 0 | 0 |
Repurchases of common stock | 0 | 0 |
Repayments of term debt | -250K | 0 |
Cash used in financing activities | 11.90M | 1.23M |
Net Change In Cash | 8.36M | 32.58K |
Cash at end of period | 8.40M | 32.58K |
| Data source | Data source |